Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does addition of temozolomide to whole brain radiotherapy improve outcome in patients with brain metastases?

Nature Clinical Practice Oncology volume 2, pages 194–195 (2005)Cite this article

boxed-textVerger E et al. (2005) Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 61: 185–191

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Andrews DW et al. (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363: 1665–1672

    Article  Google Scholar 

  2. Patchell RA et al. (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322: 494–500

    Article  CAS  Google Scholar 

  3. Bezjak A et al. (2002) Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 38: 487–496

    Article  CAS  Google Scholar 

  4. van den Bent MJ (2003) The role of chemotherapy in brain metastases. Eur J Cancer 39: 2114–2120

    Article  CAS  Google Scholar 

  5. Stupp R et al. (2004) Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) J Clin Oncol 22

Download references

Acknowledgements

The synopsis was written by Lisa Hutchinson, Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Radiation Oncology at the University of Edinburgh and Honorary Consultant Clinical Oncologist at the Edinburgh Centre for Neuro-Oncology, Edinburgh, UK

    Sara C Erridge & Anna Gregor

  2. Clinical Oncologist at the Edinburgh Centre for Neuro-Oncology, Edinburgh, UK

    Sara C Erridge & Anna Gregor

Authors
  1. Sara C Erridge
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Gregor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sara C Erridge.

Ethics declarations

Competing interests

SC Erridge has received lecture fees from Schering-Plough.

Glossary

KPS

Karnofsky Performance Status; a 0–100 scoring system to assess the wellbeing of cancer patients and their ability to perform ordinary tasks

COMPLETE RESPONSE

Defined as the disappearance of any lesion with stable or neurologic improvement, with no need for dexamethasone

PARTIAL RESPONSE

Defined as a ≥50% reduction in the sum of the areas of lesions with stable or neurologic improvement; no increase in dexamethasone required

PROGRESSION

Defined as the appearance of new lesions or increase ≥25% in lesion area, and any other situations were defined as stable disease

CTCAE v3.0

Common Terminology Criteria for Adverse Events v3.0; National Cancer Institute system for adverse event reporting that includes adverse events applicable to all oncology clinical trials regardless of chronicity or modality

BARTHEL INDEX

Scoring system for activities of daily living

EORTC QLC-C30

European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire

BR20

European Organisation for Research and Treatment of Cancer (EORTC) brain tumour quality of life questionnaireβ

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erridge, S., Gregor, A. Does addition of temozolomide to whole brain radiotherapy improve outcome in patients with brain metastases?. Nat Rev Clin Oncol 2, 194–195 (2005). https://doi.org/10.1038/ncponc0138

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0138

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing